EFFECTS OF NKTR-255, A POLYMER CONJUGATED HUMAN IL-15, ON EFFICACY OF CD19 CAR T CELL IMMUNOTHERAPY IN A PRECLINICAL LYMPHOMA MODEL.
Author(s): ,
Cassie Chou
Affiliations:
Fred Hutchinson Cancer Research Center,Seattle,United States
,
Simon Paul Fräßle
Affiliations:
Technical University Munich (TUM) Institute for Microbiology, Immunology and Hygiene,Munich,Germany
,
Reed M. Hawkins
Affiliations:
Fred Hutchinson Cancer Research Center,Seattle,United States
,
Rachel N. Steinmetz
Affiliations:
Fred Hutchinson Cancer Research Center,Seattle,United States
,
Tinh-Doan Phi
Affiliations:
Fred Hutchinson Cancer Research Center,Seattle,United States
,
Dirk H. Busch
Affiliations:
Technical University of Munich (TUM)Institute for Medical Microbiology, Immunology and Hygiene,Munich,Germany
,
Takahiro Miyazaki
Affiliations:
Nektar Therapeutics,South San Francisco,United States
,
Mario Marcondes
Affiliations:
Nektar Therapeutics,South San Francisco,United States
,
Stanley R. Riddell
Affiliations:
Fred Hutchinson Cancer Research Center,Seattle,United States
Cameron J. Turtle
Affiliations:
Fred Hutchinson Cancer Research Center,Seattle,United States
EHA Library. Chou C. 06/15/19; 266825; PS1208
Cassie Chou
Cassie Chou
Contributions
Abstract

Abstract: PS1208

Type: Poster Pitch

Presentation during EHA24: On Saturday, June 15, 2019 from 17:30 - 19:00

Location: Poster area

Background

Immunotherapy with CD19 CAR T cells achieves complete or partial remission in a fraction of patients with B cell malignancies, but disease progression remains common. IL-15 promotes T cell proliferation and survival and may enhance CAR T cell efficacy. However, exploiting native IL-15 is challenging due to its unfavorable pharmacokinetics and tolerability. In contrast, NKTR-255 is a polymer-conjugated IL-15 that retains binding affinity to IL15Rα and exhibits reduced clearance, providing sustained pharmacodynamic responses.

Aims
We investigated the effects of NKTR-255 on human CD19 CAR T cells both in vitro and in an in vivo xenogeneic B cell lymphoma model.

Methods

T cells expressing a CD19/4-1BB/CD3ζ CAR were generated from healthy donors. For in vitro studies, CAR T cells were incubated with NKTR-255 (0-100 ng/mL) with and without CD19 antigen. STAT5 phosphorylation and CFSE dilution were assessed by flow cytometry. For in vivo studies, NSG mice received 5x105 Raji lymphoma cells IV on day (D)-7 and a subtherapeutic dose (0.8x106) of CAR T cells (1:1 CD4:CD8) on D0. NKTR-255 (0.03-0.3mg/kg IV) was administered weekly starting on D-1, 7, or 14. Tumor-free mice were rechallenged with Raji cells. Tumors were assessed by bioluminescence imaging.

Results

In vitro, NKTR-255 led to dose-dependent STAT5 phosphorylation and increased antigen-dependent proliferation of CD8 CAR T cells. In vivo, infusion of NKTR-255 starting at D-1, 7 or 14 increased peak CAR T cell numbers in blood. Raji cells were eliminated from marrow by D14 in mice receiving CAR T cells and NKTR-255 on D7, but not CAR T cells alone. There was superior NKTR-255 dose-dependent tumor control and survival in mice receiving CAR T cells with NKTR-255 compared to CAR T cells or NKTR-255 alone. The benefit of combination therapy with NKTR-255 and CART T cells was greater when NKTR-255 was started by D7. Residual CAR T cells in NKTR-255-treated mice rejected re-challenge of Raji tumor cells administered beyond 5 weeks after CAR T cell infusion.

 

Conclusion

NKTR-255 administration improves the antitumor efficacy and kinetics of CD19 CAR T cells, supporting advancement into clinical trials of combination therapy with NKTR-255 and approved CD19 CAR T cell products.

Session topic: 24. Gene therapy, cellular immunotherapy and vaccination - Biology & Translational Res

Keyword(s): Immunotherapy, Lymphoma

Abstract: PS1208

Type: Poster Pitch

Presentation during EHA24: On Saturday, June 15, 2019 from 17:30 - 19:00

Location: Poster area

Background

Immunotherapy with CD19 CAR T cells achieves complete or partial remission in a fraction of patients with B cell malignancies, but disease progression remains common. IL-15 promotes T cell proliferation and survival and may enhance CAR T cell efficacy. However, exploiting native IL-15 is challenging due to its unfavorable pharmacokinetics and tolerability. In contrast, NKTR-255 is a polymer-conjugated IL-15 that retains binding affinity to IL15Rα and exhibits reduced clearance, providing sustained pharmacodynamic responses.

Aims
We investigated the effects of NKTR-255 on human CD19 CAR T cells both in vitro and in an in vivo xenogeneic B cell lymphoma model.

Methods

T cells expressing a CD19/4-1BB/CD3ζ CAR were generated from healthy donors. For in vitro studies, CAR T cells were incubated with NKTR-255 (0-100 ng/mL) with and without CD19 antigen. STAT5 phosphorylation and CFSE dilution were assessed by flow cytometry. For in vivo studies, NSG mice received 5x105 Raji lymphoma cells IV on day (D)-7 and a subtherapeutic dose (0.8x106) of CAR T cells (1:1 CD4:CD8) on D0. NKTR-255 (0.03-0.3mg/kg IV) was administered weekly starting on D-1, 7, or 14. Tumor-free mice were rechallenged with Raji cells. Tumors were assessed by bioluminescence imaging.

Results

In vitro, NKTR-255 led to dose-dependent STAT5 phosphorylation and increased antigen-dependent proliferation of CD8 CAR T cells. In vivo, infusion of NKTR-255 starting at D-1, 7 or 14 increased peak CAR T cell numbers in blood. Raji cells were eliminated from marrow by D14 in mice receiving CAR T cells and NKTR-255 on D7, but not CAR T cells alone. There was superior NKTR-255 dose-dependent tumor control and survival in mice receiving CAR T cells with NKTR-255 compared to CAR T cells or NKTR-255 alone. The benefit of combination therapy with NKTR-255 and CART T cells was greater when NKTR-255 was started by D7. Residual CAR T cells in NKTR-255-treated mice rejected re-challenge of Raji tumor cells administered beyond 5 weeks after CAR T cell infusion.

 

Conclusion

NKTR-255 administration improves the antitumor efficacy and kinetics of CD19 CAR T cells, supporting advancement into clinical trials of combination therapy with NKTR-255 and approved CD19 CAR T cell products.

Session topic: 24. Gene therapy, cellular immunotherapy and vaccination - Biology & Translational Res

Keyword(s): Immunotherapy, Lymphoma

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies